Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Methamphetamine Dependence
Intervention: Bupropion (Drug); Placebo (Other)
Phase: Phase 2
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA)
Summary
This study is to assess the efficacy of bupropion in reducing methamphetamine use in
subjects with methamphetamine dependence who report using methamphetamine 18 or less days
during the 30 days prior to the start of signing consent.
Clinical Details
Official title: Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment
Primary outcome: Abstinence
Secondary outcome: Overall reduction of use (sustained abstinence)
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI
- Must have at least 1 amphetamine or methamphetamine positive urine specimen after the
start of screening and before randomization
- Must report using methamphetamine for 18 or less days during the 30 day period prior
to the start orf screening using the Timeline Follow-back method
- Must be willing and able to comply with study procedures
- Must be able to verbalize and understand consent forms and provide written informed
consent
- Must be seeking treatment for methamphetamine dependence
Exclusion Criteria:
- Please contact study site for more information
Locations and Contacts
Addiction Phrmacology Research Laboratory, San Fransisco, California 94110, United States; Recruiting
Gannt Galloway, Pharm.D., Phone: 415-641-3370
Gannt Galloway, Pharm.D., Principal Investigator
UCLA Integrated Substance Abuse Program, Los Angeles, California 90025, United States; Recruiting
Richard A Rawson, Ph.D., Phone: 310-267-5020
Richard A Rawson, Ph.D., Principal Investigator
New York University, New York, New York 10010, United States; Recruiting
Malcolm Reid, Ph.D., Phone: 212-686-7500
Malcolm Reid, Ph.D., Principal Investigator
Medical University of South Carolina, Charleston, South Carolina 29425, United States; Recruiting
Robert Malcolm, MD, Phone: 843-792-5214
Robert Malcolm, M.D., Principal Investigator
University of Texas Health Science At San Antonio, San Antonio, Texas 78229-3900, United States; Recruiting
John D Roache, Ph.D., Phone: 210-562-5401
John D. Roache, Ph.D., Principal Investigator
Additional Information
Starting date: May 2008
Ending date: December 2010
Last updated: January 26, 2009
|
